Clinical trials: Geriatric Hematology
Acute Myeloid Leukemia, AML
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
- Trial name
- OPAL (NCT00780598)
- Testing
- Tosedostat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- Chroma Therapeutics
Leukemia
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute…
- Trial name
- NCT00003673
- Testing
- chemotherapy, gemtuzumab ozogamicin
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
- Trial name
- NCT02306291
- Testing
- GMI-1271, Mitoxantrone, Etoposide
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlycoMimetics Incorporated
Sickle Cell Disease
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease
- Trial name
- HESTIA5 (NCT04293172)
- Testing
- Brilinta
- Sponsor
- AstraZeneca
Hemophilia
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to <12 years) who have severe hemophilia A or…
- Trial name
- ATLAS-KIDS (NCT07285460)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 37 sites in United States, Belgium and 10 more
- Volunteers
- 85 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
- Trial name
- SPARK-AML1 (NCT00952588)
- Testing
- AZD1152, LDAC
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Anemia, Kidney Diseases
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
The purpose of this study is to assess disability in anemic patients over the age of 65 who have kidney disease and are receiving weekly PROCRIT® (Epoetin Alfa, a glycoprotein that stimulates red blood cell production).
- Trial name
- NCT00338468
- Testing
- epoetin alfa
- Volunteers
- 13 people
- Sponsor
- Ortho Biotech Products, L.P.
Thrombosis
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
- Trial name
- NCT01379300
- Testing
- dabigatran etexilate, rivaroxaban
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
The main purpose of this study is to determine the maximum tolerated and efficient dose of GRASPA® in combination with polychemotherapy treatment of elderly patients with ALL, 55 years and over, Philadelphia chromosome-negative…
- Trial name
- NCT01523782
- Testing
- GRASPA
- Volunteers
- 30 people
- Sponsor
- ERYtech Pharma
Anemia
Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects
Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.
- Trial name
- NCT01318551
- Testing
- BAY85-3934
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Leukemia, Acute Disease
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
- Conditions
- Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia
- Trial name
- NCT00607997
- Testing
- vosaroxin
- Where
- 20 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sunesis Pharmaceuticals
Anemia, Aged
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
The purpose of this study is to assess changes in physical function in elderly patients (>= 65 years of age) with chronic anemia (Hb <= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin…
- Conditions
- Anemia, Aged, Hemoglobins
- Trial name
- NCT00210795
- Testing
- epoetin alfa
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hematologic Diseases, Anaemia, Sickle Cell
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.
- Trial name
- NCT05660265
- Testing
- GSK4172239D
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Leukemia
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00017589
- Testing
- oblimersen sodium, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Genta Incorporated
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome…
- Trial name
- NCT01010373
- Testing
- AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
Anemia, Aged
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
The purpose of this study is to assess changes in physical function in elderly patients (>= 65 years of age) with chronic anemia (Hb <= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin…
- Conditions
- Anemia, Aged, Hemoglobins
- Trial name
- NCT00228995
- Testing
- epoetin alfa
- Volunteers
- 9 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Myeloid Leukemia
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with…
- Trial name
- NCT06389292
- Testing
- APG-2575(Lisaftoclax ), Azacitidine Injection
- Where
- 6 sites in China, Russia
- Volunteers
- 486 people
- Sponsor
- Ascentage Pharma Group Inc.
Hypereosinophilic Syndrome
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
- Trial name
- SPHERE (NCT04965636)
- Testing
- Mepolizumab
- Where
- 14 sites in United States, Argentina and 4 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline